Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Condensed Consolidated Statements of Operations and Comprehensive Loss
Revenue	$ 2,105	$ 5,125
Grant income	968	891
Total revenue and grant income	3,073	6,016
Operating Expenses
Direct costs	3,548	2,696
Research and development	17,749	19,022
Selling, general and administrative	8,122	8,327
Total operating expenses	29,419	30,045
Operating Loss	(26,346)	(24,029)
Nonoperating Income and Expense
Interest income	4,012	3,599
Change in fair value of warrant liabilities	9,642	5,879
Interest expense	(197)	(8)
Other income (expense)	17	(522)
Total nonoperating income and expense	13,474	8,948
Pretax Loss	(12,872)	(15,081)
Income tax expense	84
Share of net loss of equity method investee	72	70
Net Loss Attributable to Common Stockholders	(13,028)	(15,151)
Other Comprehensive Income (Loss)	(1,407)	173
Comprehensive Loss Attributable to Common Stockholders	$ (14,435)	$ (14,978)
Basic loss per share	$ (0.06)	$ (0.08)
Diluted loss per share	$ (0.06)	$ (0.08)
Weighted average shares outstanding - Basic	217,299,594	181,404,557
Weighted average shares outstanding - Diluted	217,299,594	181,404,557